Population-level impact of shorter-course regimens for tuberculosis: A model-based analysis

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Fofana, Mariam O ^a,b   Knight, Gwenan M ^c   Gomez, Gabriela B ^d,e   White, Richard G ^c   Dowdy, David W ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL TRANSMISSION; HUMAN; INCIDENCE; MATHEMATICAL MODEL; MORTALITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL; ALGORITHM; DISEASE COURSE; DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PROCEDURES; RECURRENT DISEASE; THEORETICAL MODEL; TIME; TRANSMISSION;

ALGORITHMS; ANTITUBERCULAR AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; TIME FACTORS; TUBERCULOSIS;

EID: 84901238788     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096389     Document Type: Article

References (38)

1. World Health Organization (2012) Global tuberculosis control 2012. Geneva: WHO.
2. Flexner C (2007) HIV drug development: The next 25 years. Nat Rev Drug Discov 6: 959-966.
3. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
4. Spigelman M, Gillespie S (2006) Tuberculosis drug development pipeline: Progress and hope. Lancet 367: 945-947.
5. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X (2010) Global tuberculosis drug development pipeline: The need and the reality. Lancet 375: 2100-2109.
6. Kruk ME, Schwalbe NR, Aguiar CA (2008) Timing of default from tuberculosis treatment: A systematic review. Trop Med Int Health 13: 703-712. (Pubitemid 351561604)
7. Maher D, Dye C, Floyd K, Pantoja A, Lonnroth K, et al (2007) Planning to improve global health: The next decade of tuberculosis control. Bull World Health Organ 85: 341-347. (Pubitemid 46718357)
8. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, et al (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331-338. (Pubitemid 44156613)
9. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, et al (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: A double-blind, randomised, controlled phase II trial. Lancet 373: 1183-1189.
10. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, et al (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet 380: 986-993.
11. Owens JP, Fofana MO, Dowdy DW (2013) Cost-effectiveness of novel first-line therapeutic regimens for tuberculosis. Int J Tuberc Lung Dis 17: 590-596.
12. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC (2005) Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293: 2767-2775. (Pubitemid 40965089)
13. Sharma S, Yoder MA (2011) New weapons in the war on tuberculosis. Am J Ther 18: e101-12.
14. Ginsberg AM, Spigelman M (2007) Challenges in tuberculosis drug research and development. Nat Med 13: 290-294. (Pubitemid 46376672)
15. Ginsberg AM (2010) Tuberculosis drug development: Progress, challenges, and the road ahead. Tuberculosis; Including a Special section celebrating Professor D A Mitchison: 60 years of contributions to the chemotherapy of tuberculosis 90: 162-167.
16. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N (2011) Mathematical models in the evaluation of health programmes. Lancet 378: 515-525.
17. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Jr, et al (2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 106: 13980-13985.
18. Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sanchez MS, et al (2006) Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 3: e273.
19. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ (2011) Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS One 6: e17601.
20. Fox W (1981) Whither short-course chemotherapy? Br J Dis Chest 75: 331-357.
21. [Anonymous] (1984) A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. Am Rev Respir Dis 130: 23-28.
22. [Anonymous] (1986) Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore tuberculosis service/British medical research council. Am Rev Respir Dis 133: 779-783.
23. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, et al (1995) The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1: 815-821.
24. Dye C, Garnett GP, Sleeman K, Williams BG (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352: 1886-1891. (Pubitemid 28561249)
25. Menzies D (1997) Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Infect Control Hosp Epidemiol 18: 582-586.
26. Sepkowitz KA (1996) How contagious is tuberculosis? Clin Infect Dis 23: 954-962.
27. Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. International Statistical Review/Revue Internationale de Statistique 62: 229-243.
28. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM (2001) High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 5: 1000-1005. (Pubitemid 33134749)
29. Jonnalagada S, Harries AD, Zachariah R, Satyanarayana S, Tetali S, et al (2011) The timing of death in patients with tuberculosis who die during antituberculosis treatment in Andhra Pradesh, South India. BMC Public Health 11: 921.
30. Moolphate S, Aung MN, Nampaisan O, Nedsuwan S, Kantipong P, et al (2011) Time of highest tuberculosis death risk and associated factors: An observation of 12 years in northern Thailand. Int J Gen Med 4: 181-190.
31. van Leth F, van der Werf MJ, Borgdorff MW (2008) Prevalence of tuberculous infection and incidence of tuberculosis: A re-assessment of the Styblo rule. Bull World Health Organ 86: 20-26.
32. Sutherland I, Svandova E, Radhakrishna S (1982) The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63: 255-268.
33. Vynnycky E, Fine PE (1997) The natural history of tuberculosis: The implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119: 183-201. (Pubitemid 27474799)
34. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, et al (2012) Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 54: 784-791.
35. Horsburgh CRJr, O'Donnell M, Chamblee S, Moreland JL, Johnson J, et al (2010) Revisiting rates of reactivation tuberculosis: A population-based approach. Am J Respir Crit Care Med 182: 420-425.
36. Harries AD, Dye C (2006) Tuberculosis. Ann Trop Med Parasitol 100: 415-431. (Pubitemid 47050865)
37. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, et al (2009) Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180: 558-563.
38. United Nations Population Division (2011) World population prospects: The 2010 revision. New York: United Nations.